中国麻风皮肤病杂志 ›› 2020, Vol. 36 ›› Issue (11): 667-671.doi: 10.12144/zgmfskin202011667

• 论著 • 上一篇    下一篇

Guselkumab治疗银屑病关节炎疗效及安全性meta分析

卢昌佩,景海霞,王润超,王恒,罗亭,步青云   

  1. 锦州医科大学十堰市太和医院研究生培养基地（湖北医药学院附属医院），湖北十堰，442000
  • 出版日期:2020-11-15 发布日期:2020-10-30
  • 通讯作者: 景海霞，E-mail: jinghaixia1210@163.com

Meta analysis of the efficacy and safety of guselkumab in the treatment of psoriatic arthritis

LU Changpei, JING Haixia, WANG Runchao, WANG Heng, LUO Ting, BU Qingyun   

  1. Postgraduate Training Basement of Jinzhou Medicical University, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
  • Online:2020-11-15 Published:2020-10-30
  • Contact: JING Haixia, E-mail: jinghaixia1210@163.com

PDF (PC)

193

摘要： 目的：评价guselkumab治疗银屑病关节炎的疗效及安全性。方法：检索Pubmed、Embase、Cochrane Library、维普期刊数据库、万方数据库及中国知网数据库与guselkumab治疗银屑病关节炎的随机对照试验（RCT），检索时间均为建库起至2020年4月。文献质量根据Cochrane系统评价进行评估。两位评论员独立选择文献并收集数据。文献用Revman 5.3软件进行meta分析。结果：纳入符合标准的文献共3篇，共涉及896例银屑病关节炎患者，试验组475例，对照组421例。meta分析结果示皮下注射guselkumab与安慰剂比较，在第24周时能显著提高达到ACR 20，ACR 50，ACR 70和PASI 75，PASI 90患者的例数；HAQ-D1较基线提高0.35的患者例数也高于安慰剂组；Guselkumab与安慰剂比较，总的不良事件的发生率方面差异无统计学意义。结论：Guselkumab是改善银屑病关节炎安全、有效的选择。

关键词: guselkumab, 银屑病关节炎, meta分析

Abstract: Objective: To assess the efficacy and safety of guselkumab in the treatment of patients with psoriatic arthritis. Methods: Randomized controlled trials (RCTs) on guselkumab for psoriatic arthritis were searched in the websites of Pubmed, Embase, Cochrane Library, CNKI, Wanfang Database and VIP datebase from inception to April 2020. The quality of articles was evaluated according to Cochrane systematic review. Two reviewers independently selected literature and extracted data. Meta analysis was performed using Revman 5.3 software. Results: A total of 3 articles were included, involving 896 patients with psoriatic arthritis (475 in the experimental group, and 421 in the control group). Meta-analysis indicated that the number of patients reached to ACR 20, ACR 70 and PASI 75, PASI 90 was more in the guselkumab group than in the placebo group at week 24.  The patients with HAQ-D1 increased by 0.35 from baseline were also higher in the guselkumab group than in the placebo group. There was no statistically significant difference in the incidence of the adverse events between the guselkumab group and the placebo group. Conclusion: Guselkumab is effective and safe in the treatment of the patients with psoriatic arthritis.

Key words: guselkumab, psoriatic arthritis, meta analysis